1 Min Read
Feb 14 (Reuters) - Amgen Inc :
* Amgen says submits supplemental Biologics license application for Blincyto in relapsed or refractory b-cell precursor acute lymphoblastic leukemia Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.